My philosophy is simple: buy low and sell high.
By any number of measures this market is getting pricey.
Soaring LinkedIn and Twitter will fall back to earth.
Bracing for downside risk has not been rewarded in the recent past.
The FDA’s rejection of Aveo’s Tivozanib is a stunner.
The FDA has let down renal cancer patients with its Tivozanib decision.
Aveo’s Tivozanib kidney cancer drug will get the nod from regulators.
Beware market sages offering investment advice.
When it comes to investing, the right temperament is crucial.